Medications with Generic Name Beginning ‘A’

Page 1 of 563 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

Aurodex (A/B Otic Drops)

Acute Otitis Media of Various Etiologies. Prompt relief of pain and reduction of inflammation in the congestive and serous stages – Adjuvant therapy during systemic antibiotic administration for rsolution of the infection. Because the close…

Preferred Pharmaceuticals, Inc13 May 2013

Abacavir

Abacavir tablets USP 300mg, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (1) Abacavir tablets USP 300…

Strides Shasun Limited6 January 2017

Abacavir

Abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Abacavir tablets, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase…

Avera McKennan Hospital22 March 2017

Abacavir

Abacavir oral solution in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Abacavir oral solution, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse…

Camber Pharmaceuticals, Inc.13 September 2017

Abacavir

Abacavir tablet, a nucleoside analogue human immunodeficiency virus (HIV-1) reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment…

Cipla USA Inc.5 June 2018

Page 1 of 563 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Precision Dose Inc. Issues Voluntary Nationwide Recall of Ranitidine Oral Solution, USP 150 mg/10 mL Due to Possible Presence of N-nitrosodimethylamine (NDMA) Impurity
Mon, 18 Nov 2019. Precision Dose Inc. is voluntarily recalling 5 lots of Ranitidine Oral Solution, USP 150 mg/10 mL to the consumer level. Ranitidine Oral Solution, USP 150 mg/10 mL, is being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above…
Update On Device Failure Associated with Getinge’s Maquet/Datascope Intra-Aortic Balloon Pumps – Letter to Health Care Providers
Mon, 18 Nov 2019. The U.S. Food and Drug Administration (FDA) is providing an update on our evaluation of device failures associated with Getinge's Maquet/Datascope intra-aortic balloon pump (IABP) devices: Cardiosave (Hybrid and Rescue), CS300 and CS100/CS100i.

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.